S. Karger AG

SHERPA: Unknown

People

  1. Sklar
    Sklar
  2. Hay
    Hay
  3. Horwitz
    Horwitz
  4. Offit
    Offit
  5. Vickers
    Vickers
  6. Halpern
    Halpern
  7. Hamilton
    Hamilton
  8. Dusza
    Dusza
  9. Li
    Li
  10. Marghoob
    Marghoob

Groups

  1. Population Sciences Research Program (36)
  2. Survivorship Research (20)
  3. Department of Medicine (14)
  4. Epidemiology and Biostatistics (13)
  5. Pediatrics, Department of (10)
  6. General Oncology Service (9)
  7. Behavioral Sciences Service (7)
  8. Health Outcomes Research Group (7)
  9. Psychiatry and Behavioral Sciences, Department of (7)
  10. Center for Hematologic Malignancies (6)
Search Within
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (23)
  2. Meeting Abstract (10)
  3. Review (3)
Groups
  1. Population Sciences Research Program (36)
  2. Survivorship Research (20)
  3. Department of Medicine (14)
  4. Epidemiology and Biostatistics (13)
  5. Pediatrics, Department of (10)
  6. General Oncology Service (9)

More Groups

People
  1. Charles Sklar (8)
  2. Andrew Vickers (4)
  3. Jada Hamilton (4)
  4. Jennifer Hay (4)
  5. Kenneth Offit (4)
  6. Steven Horwitz (4)

More People

Years
  1. 2025 (1)
  2. 2023 (2)
  3. 2022 (1)
  4. 2021 (2)
  5. 2020 (3)
  6. 2019 (4)

More Years

Publications
  1. Public Health Genomics (7)
  2. Hormone Research in Paediatrics (4)
  3. Oncology Research and Treatment (4)
  4. Dermatology (3)
  5. Hormone Research (3)
  6. Human Heredity (3)

More Publications

Results (36)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pediatric DTC genetic testing for adult-onset inherited cancer risk: The perspectives of high-risk parents
    Journal Article

    Kilbride, M. K.; Peshkin, B. N.; Hamilton, J. G.; Brower, J.; Ovadia, H.; Ross, L. F.; Sacca, R.; Tarini, B.; Domchek, S. M.; Vittone, S.; more...
    Public Health Genomics (2025)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Patient-reported receipt of oncology clinician-delivered brief tobacco treatment (5As) six months following cancer diagnosis
    Journal Article

    Price, S. N.; Neil, J. M.; Flores, M.; Ponzani, C.; Muzikansky, A.; Ballini, L.; Ostroff, J. S.; Park, E. R.
    Oncology (2023)

    Fulltext@MSK | Save
  • Advances in the etiology, detection, and clinical management of seborrheic keratoses
    Review

    Sun, M. D.; Halpern, A. C.
    Dermatology (2022)

    Fulltext@MSK | Save
  • ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Exome-wide pan-cancer analysis of germline variants in 8,719 individuals finds little evidence of rare variant associations
    Journal Article

    Guan, Z.; Shen, R.; Begg, C. B.
    Human Heredity (2021)

    Fulltext@MSK | Save
  • Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A+CHP) for patients (pts) with CD30+ peripheral T-cell lymphoma (ECHELON-2)
    Meeting Abstract

    Trümper, L.; Pro, B.; Horwitz, S.; O'connor, O.; Tilly, H.; Choi, I.; Gritti, G.; Fox, C.; Alpdogan, O.; Mayer, J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Illustrating cancer risk: Patient risk communication preferences and interest regarding a novel BRCA1/2 genetic risk modifier test
    Journal Article

    Hamilton, J. G.; Genoff Garzon, M.; Shah, I. H.; Cadet, K.; Shuk, E.; Westerman, J. S.; Hay, J. L.; Offit, K.; Robson, M. E.
    Public Health Genomics (2020)

    Fulltext@MSK | Save
  • Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry
    Journal Article

    Lansigan, F.; Horwitz, S. M.; Pinter-Brown, L. C.; Rosen, S. T.; Pro, B.; Hsi, E. D.; Federico, M.; Gisselbrecht, C.; Schwartz, M.; Bellm, L. A.; more...
    Acta Haematologica (2020)

    Fulltext@MSK | Save
  • The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs)
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T. M.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save